Clinical impact and characteristics of erythroid dysplasia in adult aplastic anaemia: Results from a multicentre registry
Tomoya Maeda,Akira Matsuda,Junya Kanda,Hiroshi Kawabata,Takayuki Ishikawa,Kaoru Tohyama,Akira Kitanaka,Kayano Araseki,Kei Shimbo,Tomoko Hata,Takahiro Suzuki,Hidekazu Kayano,Kensuke Usuki,Maki Shindo‐Ueda,Nobuyoshi Arima,Masaharu Nohgawa,Akiko Ohta,Shigeru Chiba,Yasushi Miyazaki,Shinji Nakao,Keiya Ozawa,Shunya Arai,Mineo Kurokawa,Akifumi Takaori‐Kondo,Kinuko Mitani,the Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes
DOI: https://doi.org/10.1111/bjh.19323
2024-02-02
British Journal of Haematology
Abstract:It is difficult to distinguish between MDS and AA in clinical practice, especially when only erythroid dysplasia is present in patients who have bone marrow hypoplasia without an increase in blasts. In the morphological diagnosis of MDS and AA, the central review team in Japan distinguishes between the two diseases by especially focusing on the number of MgK. In this study, we found that erythroid dysplasia is also observed in AA and does not significantly affect the clinical features or impact the outcome of patients with AA. In conclusion, the finding of erythroid dysplasia alone should not exclude a diagnosis of AA. AA, aplastic anaemia; MDS, myelodysplastic neoplasms; MgK, megakaryocytes; OS, overall survival. Summary Morphological dysplasia in haematopoietic cells, defined by a 10% threshold in each lineage, is one of the diagnostic criteria for myelodysplastic neoplasms. Dysplasia limited to the erythroid lineage has also been reported in some cases of aplastic anaemia (AA); however, its significance remains unclear. We herein examined the impact of erythroid dysplasia on immunosuppressive therapy responses and survival in AA patients. The present study included 100 eligible AA patients without ring sideroblasts. Among them, 32 had dysplasia in the erythroid lineage (AA with minimal dysplasia [mini‐D]). No significant sex or age differences were observed between AA groups with and without erythroid dysplasia. In severe/very severe AA and non‐severe AA patients, a response to anti‐thymocyte globulin + ciclosporin within 12 months was observed in 80.0% and 60.0% of AA with mini‐D and 42.9% and 90.0% of those without dysplasia, with no significant difference (p = 0.29 and p = 0.24 respectively). Overall survival and leukaemia‐free survival did not significantly differ between the groups. Collectively, the present results indicate that the presence of erythroid dysplasia did not significantly affect clinical characteristics or outcomes in AA patients, suggesting that its presence in AA is acceptable. Therefore, erythroid dysplasia should not exclude an AA diagnosis.
hematology